Table 1.

Clinicopathological characteristics of 137 primary breast carcinomas

Total number of patients137
Age, median years (range)56 (26–92)
Grading
 111 (8%)
 266 (48.2%)
 360 (43.8%)
Node
 Negative60 (43.8%)
 Positive77 (56.2%)
HR status
 ER and/or PgR positive82 (59.8%)
 ER negative PgR negative55 (40.2%)
HER2 status
 0/1+/2+NA112 (81.7%)
 2+A/3+25 (18.3%)
Neoadjuvant/adjuvant therapy
 Anthracycline-based46 (33.6%)
 Taxane-based8 (5.8%)
 Anthracycline plus taxane-based5 (3.7%)
 Other30 (21.9%)
 Hormone40 (29.2%)
 None8 (5.8%)
First metastatic site
 Visceral diseasea26 (19%)
 Nonvisceral diseaseb111 (81%)
Median DFS (months/range)45.4 (1–94)

Abbreviations: HR, hormonal receptor; ER, estrogen receptor; PgR, progesterone receptor; NA, nonamplified; A, amplified; DFS, disease free survival.

  • aVisceral: liver, pleura, lung, and ovary.

  • bNonvisceral: lymph node, soft tissue, and local recurrence.